Biotech News
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases.
Related news
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
SRPTSarepta Therapeutics2026-08-31 20:30 EST
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SRPTSarepta Therapeutics2026-07-29 21:00 EST
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-09-04 12:50 EST
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
INVAInnoviva2026-08-11 20:05 EST
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
KYMRKymera2026-07-07 11:00 EST
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-09-01 07:00 EST
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
GSKGSK plc2026-08-24 07:01 EST
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
GSKGSK plc2026-08-24 07:00 EST
Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
Stock data
- Close
- 50.87 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States